3D imaging of the response to CDC25 inhibition in multicellular spheroids

Cancer Biology and Therapy

Volumn 8, Issue 23, 2009, Pages 2228-2234

  Frongia, Céline ^a,b   Lorenzo, Corinne ^a,b   Gianni, Fréderic ^b,c   Prevost, Grégoire Pierre ^d   Ducommun, Bernard ^a,b,e   Lobjois, Valérie ^a,b  

^a CNRS   (France)

^b UNIVERSITÉ DE TOULOUSE   (France)

^c IRIT   (France)

^d Institut Henri Beaufour   (France)

^e CHU PURPAN   (France)

Author keywords

3D imaging; CDC25; Cell cycle; Colon cancer; Cytotoxicity; Multicellular tumor spheroids; Pharmacology

Indexed keywords

ANTINEOPLASTIC AGENT; IRC 083864; PROTEIN TYROSINE PHOSPHATASE; UNCLASSIFIED DRUG;

ARTICLE; CELL DEATH; CONTROLLED STUDY; CYTOTOXICITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; LASER MICROSCOPY; MITOSIS INHIBITION; MULTICELLULAR SPHEROID; PHOTON; THREE DIMENSIONAL IMAGING; TUMOR SPHEROID;

EID: 73949159260     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.8.23.9984     Document Type: Article

References (32)

1. Desoize B, Jardillier J. Multicellular resistance: a paradigm for clinical resistance? Critical reviews in oncology/hematology 2000; 36:193-207.
2. Horiatis D, Wang Q, Pinski J. A new screening system for proliferation-independent anti-cancer agents. Cancer letters 2004; 210:119-24.
3. Desoize B. Contribution of three-dimensional culture to cancer research. Critical reviews in oncology/hematology 2000; 36:59-60.
4. Kunz-Schughart LA. Multicellular tumor spheroids: intermediates between monolayer culture and in vivo tumor. Cell biology international 1999; 23:157-61.
5. Sutherland RM. Cell and environment interactions in tumor microregions: the multicell spheroid model. Science (New York, NY) 1988; 240:177-84.
6. Mellor HR, Ferguson DJ, Callaghan R. A model of quiescent tumour microregions for evaluating multicellular resistance to chemotherapeutic drugs. British journal of cancer 2005; 93:302-9.
7. Boutros R, Dozier C, Ducommun B. The when and wheres of CDC25 phosphatases. Current opinion in cell biology 2006; 18:185-91.
8. Boutros R, Lobjois V, Ducommun B. CDC25 phosphatases in cancer cells: key players? Good targets? Nature reviews 2007; 7:495-507.
9. Brezak MC, Quaranta M, Contour-Galcera MO, Lavergne O, Mondesert O, Auvray P, et al. Inhibition of human tumor cell growth in vivo by an orally bioavailable inhibitor of CDC25 phosphatases. Molecular cancer therapeutics 2005; 4:1378-87.
10. Brezak MC, Quaranta M, Mondesert O, Galcera MO, Lavergne O, Alby F, et al. A novel synthetic inhibitor of CDC25 phosphatases: BN82002. Cancer research 2004; 64:3320-5.
11. Brisson M, Foster C, Wipf P, Joo B, Tomko RJ Jr, Nguyen T, Lazo JS. Independent mechanistic inhibition of cdc25 phosphatases by a natural product caulibugulone. Molecular pharmacology 2007; 71:184-92.
12. Brisson M, Nguyen T, Vogt A, Yalowich J, Giorgianni A, Tobi D, et al. Discovery and characterization of novel small molecule inhibitors of human Cdc25B dual specificity phosphatase. Molecular pharmacology 2004; 66:824-33.
13. Brun MP, Braud E, Angotti D, Mondesert O, Quaranta M, Montes M, et al. Design, synthesis and biological evaluation of novel naphthoquinone derivatives with CDC25 phosphatase inhibitory activity. Bioorganic & medicinal chemistry 2005; 13:4871-9.
14. Cao S, Foster C, Brisson M, Lazo JS, Kingston DG. Halenaquinone and xestoquinone derivatives, inhibitors of Cdc25B phosphatase from a Xestospongia sp. Bioorganic & medicinal chemistry 2005; 13:999-1003.
15. Cheon HG, Kim SM, Yang SD, Ha JD, Choi JK. Discovery of a novel protein tyrosine phosphatase-1B inhibitor, KR61639: potential development as an antihyperglycemic agent. European journal of pharmacology 2004; 485:333-9.
16. Contour-Galcera MO, Lavergne O, Brezak MC, Ducommun B, Prevost G. Synthesis of small molecule CDC25 phosphatases inhibitors. Bioorganic & medicinal chemistry letters 2004; 14:5809-12.
17. Cossy J, Belotti D, Brisson M, Skoko JJ, Wipf P, Lazo JS. Biological evaluation of newly synthesized quinoline-5,8-quinones as Cdc25B inhibitors. Bioorganic & medicinal chemistry 2006; 14:6283-7.
18. Kar S, Wang M, Ham SW, Carr BI. H32, a non-quinone sulfone analog of vitamin K3, inhibits human hepatoma cell growth by inhibiting Cdc25 and activating ERK. Cancer biology & therapy 2006; 5:1340-7.
19. Kim KR, Kwon JL, Kim JS, No Z, Kim HR, Cheon HG. EK-6136 (3-methyl-4-(O-methyl-oximino)-1-phenylpyrazolin-5-one): a novel Cdc25B inhibitor with antiproliferative activity. European journal of pharmacology 2005; 528:37-42.
20. Lazo JS, Aslan DC, Southwick EC, Cooley KA, Ducruet AP, Joo B, et al. Discovery and biological evaluation of a new family of potent inhibitors of the dual specificity protein phosphatase Cdc25. Journal of medicinal chemistry 2001; 44:4042-9.
21. Lazo JS, Nunes R, Skoko JJ, Queiroz de Oliveira PE, Vogt A, Wipf P. Novel benzofuran inhibitors of human mitogen-activated protein kinase phosphatase-1. Bioorganic & medicinal chemistry 2006; 14:5643-50.
22. Sohn J, Kiburz B, Li Z, Deng L, Safi A, Pirrung MC, Rudolph J. Inhibition of Cdc25 phosphatases by indolyldihydroxyquinones. Journal of medicinal chemistry 2003; 46:2580-8.
23. Brezak MC, Valette A, Quaranta M, Contour-Galcera MO, Jullien D, Lavergne O, et al. IRC-083864, a novel bis quinone inhibitor of CDC25 phosphatases active against human cancer cells. International journal of cancer 2009; 124:1449-56.
24. Friedrich J, Ebner R, Kunz-Schughart LA. Experimental anti-tumor therapy in 3-D: spheroids - old hat or new challenge? International journal of radiation biology 2007; 83:849-71.
25. Friedrich J, Seidel C, Ebner R, Kunz-Schughart LA. Spheroid-based drug screen: considerations and practical approach. Nature protocols 2009; 4:309-24.
26. Kunz-Schughart LA, Freyer JP, Hofstaedter F, Ebner R. The use of 3-D cultures for high-throughput screening: the multicellular spheroid model. J Biomol Screen 2004; 9:273-85.
27. Truchet I, Jozan S, Baron S, Frongia C, Balaguer P, Richard-Foy H, Valette A. Estrogen and antiestrogen-dependent regulation of breast cancer cell proliferation in multicellular spheroids: Influence of cell microenvironment. International journal of oncology 2008; 32:1033-9.
28. le Roux L, Volgin A, Maxwell D, Ishihara K, Gelovani J, Schellingerhout D. Optimizing imaging of three-dimensional multicellular tumor spheroids with fluorescent reporter proteins using confocal microscopy. Mol Imaging 2008; 7:214-21.
29. Lobjois V, Frongia C, Jozan S, Truchet I, Valette A. Cell cycle and apoptotic effects of SAHA are regulated by the cellular microenvironment in HCT116 multicellular tumour spheroids. Eur J Cancer 2009.
30. Aressy B, Ducommun B. Cell cycle control by the CDC25 phosphatases. Anti-cancer agents in medicinal chemistry 2008; 8:818-24.
31. Del Duca D, Werbowetski T, Del Maestro RF. Spheroid preparation from hanging drops: characterization of a model of brain tumor invasion. J Neurooncol 2004; 67:295-303.
32. Timmins NE, Nielsen LK. Generation of multicellular tumor spheroids by the hanging-drop method. Methods in molecular medicine 2007; 140:141-51.